Business Context and Reporting Period
This Form 8-K filing by CytoSorbents Corp (Cytosorbents Corporation) reports on events occurring on June 30, 2016. The Company, along with its wholly owned subsidiary CytoSorbents Medical, Inc., entered into a material definitive agreement to secure financing for working capital and general business requirements.
Key Financial Metrics and Debt Structure
The filing details a new debt facility rather than historical operating performance metrics such as revenue or profit.
- Total Loan Commitment: Up to $10 million in aggregate.
- Tranche Structure: Two equal tranches of $5 million each (Term A Loan and Term B Loan).
- Interest Rate: Floating per annum rate based on the Effective Interest Rate defined in the agreement.
- Repayment Terms: Monthly interest payments commence the month after funding. Principal and interest payments begin August 1, 2017 (if Term B is not made) or February 1, 2018 (if Term B is made).
- Maturity Date: July 1, 2020.
- Closing Fee: Non-refundable fee of $50,000.
- Final Fee: 2.5% of the principal amount of each funded Term Loan, payable at maturity or upon prepayment/acceleration.
- Prepayment Fees: 2.0% (within first year), 1.5% (second year), or 1.0% (after second year through June 30, 2020) of the prepaid principal amount.
Material Changes and Agreements
The primary material change is the execution of the Loan and Security Agreement with Bridge Bank, a division of Western Alliance Bank. The obligations are secured by a first priority security interest in the Borrower's shares and collateral, explicitly excluding intellectual property. Additionally, the Borrower entered into a Success Fee Letter.
Guidance, Risks, and Contingencies
Success Fee Contingency: The Company agreed to pay a success fee equal to 6.37% of the funded amount of the Term Loans upon the occurrence of a "Liquidity Event." This fee obligation terminates on June 30, 2021.
Liquidity Event Triggers:
- Sale or disposition of all or substantially all assets.
- Merger or consolidation where existing holders lose majority voting control.
- Change in control where a person or group gains the power to elect a majority of the Board of Directors.
- Stock Price Trigger: Closing price per share on NASDAQ Capital Market reaches $8.00 or more for five successive business days.
Payment Option for Stock Trigger: If the success fee is triggered by the stock price reaching $8.00, the Company may elect to pay in shares of common stock rather than cash, calculated based on the volume-weighted average price of the five-day period.
Events of Default: Include non-payment, failure to perform obligations, Material Adverse Events, attachment/seizure of material assets, and insolvency proceedings.
Investor Verification Checklist
- Verify the actual disbursement status of the Term A and Term B loans (whether the full $10 million was funded).
- Confirm the current effective interest rate applied to the outstanding balance.
- Monitor the Company's stock price relative to the $8.00 threshold to assess potential dilution from the success fee payment option.
- Review the specific definition of "Material Adverse Event" in the attached Loan and Security Agreement (Exhibit 10.1).
- Assess the impact of the 2.5% final fee and potential prepayment penalties on future liquidity planning.